Cited by 518Lung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina Chiara, Han, Ji-Youn, Katakami, Nobuyuki, Kim, Hye Ryun, Hodge, Rachel, Kaur, Paramjit, Brown, Andrew P., Ghiorghiu, Dana, Papadimitrakopoulou, Vassiliki A., Mok, Tony S.K.·2018·Journal of Clinical Oncology

DOI 10.1200/jco.2018.77.9363

Open this paper in CoChat — free account

Abstract

Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression. We report the first comparative evidence of osimertinib CNS efficacy versus platinum-pemetrexed from a phase III study (AURA3; ClinicalTrials.gov identifier: NCT02151981) in patients with EGFR T790M-positive advanced NSCLC who experience disease progression with prior EGFR-tyrosine kinase inhibitor treatment. Methods Patients with asymptomatic, stable CNS metastases were eligible for enrollment and were randomly assigned 2:1 to osimertinib 80 mg once daily or platinum-pemetrexed. A preplanned subgroup analysis was conducted in patients with measurable and/or nonmeasurable CNS lesions on baseline brain scan by blinded independent central neuroradiological review. The CNS evaluable for response set included only patients with one or more measurable CNS lesions. The primary objective for this analysis was CNS objective response rate (ORR). Results Of 419 patients randomly assigned to treatment, 116 had measurable and/or nonmeasurable CNS lesions, including 46 patients with measurable CNS lesions. At data cutoff (April 15, 2016), CNS ORR in patients with one or more measurable CNS lesions was 70% (21 of 30; 95% CI, 51% to 85%) with osimertinib and 31% (5 of 16; 95% CI, 11% to 59%) with platinum-pemetrexed (odds ratio, 5.13; 95% CI, 1.44 to 20.64; P = .015); the ORR was 40% (30 of 75; 95% CI, 29% to 52%) and 17% (7 of 41; 95% CI, 7% to 32%), respectively, in patients with measurable and/or nonmeasurable CNS lesions (odds ratio, 3.24; 95% CI, 1.33 to 8.81; P = .014). Median CNS duration of response in patients with measurable and/or nonmeasurable CNS lesions was 8.9 months (95% CI, 4.3 months to not calculable) for osimertinib and 5.7 months (95% CI, 4.4 to 5.7 months) for platinum-pemetrexed; median CNS progression-free survival was 11.7 months and 5.6 months, respectively (hazard ratio, 0.32; 95% CI, 0.15 to 0.69; P = .004). Conclusion Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC.

Integrity signals

Registry

Crossref · 10.1200/jco.2018.77.9363

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna, P., Nankivell, M. G., Barton, R., Finn, C. F., Wilson, P., McColl, E., MOORE, B. J., Brisbane, I., Ardron, D., Holt, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30825-x · Cited by 723
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., Sakamori, Y., Nagai, H., Kim, Y. H., Katsura, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1929-4 · Cited by 282
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease
Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
Goss, G., Tsai, C.-M., Shepherd, F. A., Ahn, M.-J., Bazhenova, L., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx820 · Cited by 247
Self-citation

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 101–200 of 518

Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery
Colclough, N., Chen, K., Johnström, P., Fridén, M., & McGinnity, D. F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.01.015 · Cited by 43
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Popat, S., Ahn, M., Ekman, S., Leighl, N. B., Ramalingam, S. S., Reungwetwattana, T., Siva, S., Tsuboi, M., Wu, Y.-L. L. C., & Yang, J. C. (2023) · Targeted Oncology · doi:10.1007/s11523-022-00941-7 · Cited by 39
Self-citation
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study
Ji, J., Aredo, J. V., Piper‐Vallillo, A. J., Huppert, L. A., Rotow, J. K., Husain, H., Stewart, S., Cobb, R. G., Wakelee, H. A., Blakely, C. M., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100459 · Cited by 38
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis
Souza, V. G. P., de Araújo, R. P., Santesso, M. R., Seneda, A. L., Minutentag, I. W., Felix, T. F., Filho, P. T. H., Pewarchuk, M. E., Brockley, L. J., Marchi, F. A., et al. (2023) · Cancers · doi:10.3390/cancers15030722 · Cited by 42
Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
Mansouri, A., Ozair, A., Bhanja, D., Wilding, H. E., Mashiach, E., Haque, W. Z., Mikolajewicz, N., Filho, L. D. M., Mahase, S. S., Machtay, M. X., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01013-1 · Cited by 41
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
Zhang, Y., He, B., Zhou, D., Li, M., & Hu, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s188612 · Cited by 38
The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease
Zeng, Y., Ni, J., Yu, F., Zhou, Y., Zhao, Y., Li, S., Guo, T., Chu, L., Yang, X., Chu, X., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01651-y · Cited by 38
International consensus on radiotherapy in metastatic non-small cell lung cancer
Zhu, Z., Ni, J., Cai, X., Su, S., Zhuang, H., Yang, Z., Chen, M., Ma, S., Xie, C., Xu, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-644 · Cited by 39
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib
Peled, N., Tufman, A., Sequist, L. V. D., Pasello, G., Wang, Q., Antonuzzo, L., González-Larriba, J. L., Valdivieso, S. M., Cobo, M., Milella, M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105807 · Cited by 37
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Xing, L., Pan, Y., Shi, Y., Shu, Y., Feng, J., Li, W., Cao, L., Wang, L., Gu, W., Song, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2081 · Cited by 37
Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment
Li, J., & Kwok, H. F. (2020) · Cancers · doi:10.3390/cancers12061587 · Cited by 37
Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier
Wang, X., Mao, W., Wang, Z., Li, X., Xiong, Y., Lu, H., Wang, X., Yin, H., Cao, X., & Xin, H. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s258699 · Cited by 36
Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis
Lu, X., Gao, C., Liu, C., Zhuang, J., Su, P., Li, H., Wang, X., & Sun, C. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152475 · Cited by 35
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Papini, F., Sundaresan, J., Leonetti, A., Tiseo, M., Rolfo, C. D., Peters, G. J., & Giovannetti, E. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103454 · Cited by 35
Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells
Skupin-Mrugalska, P., & Minko, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100939 · Cited by 34
Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer
Cheema, P. K., Gomes, M. M., Banerji, S. O., Joubert, P., Leighl, N. B., Melosky, B. L., Sheffield, B. S., Stockley, T. L., & Ionescu, D. N. (2020) · Current Oncology · doi:10.3747/co.27.7297 · Cited by 34
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
Remón, J., Besse, B., Aix, S. P., Callejo, A., Al-Rabi, K. H., Bernabé, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01521 · Cited by 33
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3
Gray, J. E., Markovets, A. A., Reungwetwattana, T., Majem, M., Nogami, N., Peled, N., Lee, J. S., Cho, B. C., Chewaskulyong, B., John, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.07.008 · Cited by 33
Self-citation
Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLC
Li, Y.-S., Lai, W., Yin, K., Zheng, M.-M., Tu, H., Guo, W., Li, L., Lin, S., Wang, Z., Zeng, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114613 · Cited by 34
Self-citation
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
Lü, S., Ahn, M.-J., Reungwetwattana, T., Özgüroğlu, M., Kato, T., Yang, J. C., Huang, M., Fujiki, F., Inoue, T., Quang, L.-V., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2243 · Cited by 32
Self-citation
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Jung, H. A., Woo, S., Lee, S., Ahn, J. S., Ahn, M., Park, K., & Sun, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-379 · Cited by 32
Self-citation
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
Liu, L., Wang, C., Li, S., Bai, H., & Wang, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-572 · Cited by 36
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients
Alvarez-Breckenridge, C. A., Remón, J., Piña, Y., Nieblas‐Bedolla, E., Forsyth, P. A., Hendriks, L. E. L., & Brastianos, P. K. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_352320 · Cited by 32
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
John, T., Grohé, C., Goldman, J. W., Shepherd, F. A., de Marinis, F., Kato, T., Wang, Q., Su, W., Choi, J., Sriuranpong, V., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.015 · Cited by 32
Self-citation
Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors
Zhou, Y., Wang, B., Qu, J., Yu, F., Zhao, Y., Li, S., Zeng, Y., Yang, X., Chu, L., Chu, X., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.018 · Cited by 31
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
Lee, J., & Ahn, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102291 · Cited by 31
Self-citation
Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Liam, C. K. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.12.68 · Cited by 31
Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies
Wu, D., Sun, Q., Tang, H., Xiao, H., Luo, J., Ouyang, L., & Sun, Q. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101176 · Cited by 32
Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
Ohe, Y., Kato, T., Sakai, F., Kusumoto, M., Endo, M., Saito, Y., Baba, T., Sata, M., Yamaguchi, O., Sakamoto, K., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa067 · Cited by 30
Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses
Zhao, B., Wang, Y., Wang, Y., Chen, W., Zhou, L., Liu, P. H., Kong, Z., Dai, C., Wang, Y., & Ma, W. (2020) · Aging · doi:10.18632/aging.103455 · Cited by 30
Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data
Tan, K., Bryan, J., Segal, B. D., Bellomo, L. P., Nussbaum, N., Tucker, M., Torres, A. Z., Bennette, C., Capra, W. B., Curtis, M. D., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2351 · Cited by 32
Strategies to Preserve Cognition in Patients With Brain Metastases: A Review
Robin, T. P., & Rusthoven, C. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00415 · Cited by 31
Safety of osimertinib in EGFR -mutated non-small cell lung cancer
Mezquita, L., Varga, A., & Planchard, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1549222 · Cited by 31
Stereotactic Radiosurgery as Treatment for Brain Metastases: An Update
Pino, I. P., & Chen, C. C. (2023) · Asian Journal of Neurosurgery · doi:10.1055/s-0043-1769754 · Cited by 31
Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
Zhou, J., Zhao, C., Zhao, J., Wang, Q., Chu, X., Li, J., Zhou, F., Ren, S., Li, X., Su, C., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13035 · Cited by 29
Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
Nieva, J. J., Reckamp, K. L., Potter, D. M., Taylor, A., & Sun, P. (2022) · Drugs - Real World Outcomes · doi:10.1007/s40801-022-00302-w · Cited by 29
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28
Efficacy of PD ‐1/ PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
Sheng, J., Li, H., Yu, X., Yu, S., Chen, K., Pan, G., Xie, M., Li, N., Zhou, Z., & Fan, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14171 · Cited by 28
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Majem, M., Goldman, J. W., John, T., Grohe, C., Laktionov, K., Kim, S.-W., Kato, T., Vũ, H. V., Lu, S., Li, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3530 · Cited by 28
Self-citation
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors
Hong, M. H., Choi, Y. J., Ahn, H. K., Lim, S. M., Keam, B., Kim, D., Kim, T. M., Youk, J., Kim, Y. J., Hwang, S., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.2640 · Cited by 27
Self-citation
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
Bergonzini, C., Leonetti, A., Tiseo, M., Giovannetti, E., & Peters, G. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1746269 · Cited by 28
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR ‐mutated non‐small cell lung cancer patients with brain metastases
Yu, X., Sheng, J., Pan, G., & Fan, Y. (2021) · International Journal of Cancer · doi:10.1002/ijc.33677 · Cited by 27
A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma
Sharma, M., Basu, D. A., Nathany, S., Amrith, B. P., & Batra, U. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_222_22 · Cited by 28
Canadian Consensus: A New Systemic Treatment Algorithm for Advanced EGFR-Mutated Non-Small-Cell Lung Cancer
Melosky, B. L., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Liu, G., & Cheema, P. K. (2020) · Current Oncology · doi:10.3747/co.27.6007 · Cited by 27
Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
Zhai, X., Li, W., Li, J., Jia, W., Wang, J., Tian, Y., Xu, S., Li, Y., Zhu, H., & Yu, J. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01955-7 · Cited by 27
Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRASG12C-Mutant Non–Small-Cell Lung Cancer
Lamberti, G., Aizer, A. A., Ricciuti, B., Alessi, J. V., Pecci, F., Tseng, S.-C., Sholl, L. M., Nishino, M., & Awad, M. M. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00621 · Cited by 26
What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule
Rodon, J. A., Gray, N. S., Mok, T. S. K., & Gainor, J. F. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_242209 · Cited by 27
Self-citation
Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial)
Arrieta, O. G., Maldonado, F., Turcott, J. G., Zatarain-Barrón, Z. L., Barrón, F., Blake-Cerda, M., Cabrera-Miranda, L. A., Cardona, A. F., Garza, J. G. D. L., & Rosell, R. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.02.044 · Cited by 25
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Wilcox, J. A., & Boire, A. A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00975-5 · Cited by 25
Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
Jablonska, P. A., Bosch‐Barrera, J., Serrano, D., Valiente, M., Calvo, A., & Aristu, J. (2021) · Cancers · doi:10.3390/cancers13092141 · Cited by 24
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 24
Lazertinib: on the Way to Its Throne
Lee, J., Hong, M. H., & Cho, B. C. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.9.799 · Cited by 24
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
Hou, H., Sun, D., Zhang, C., Liu, D., & Zhang, X. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13817 · Cited by 23
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide, I. J. Z., Stensgaard, S., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., Cicėnas, S., Koivunen, J. P., Grønberg, B. H., Sørensen, B. S., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-995 · Cited by 23
Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M mutation
Wang, G., Zhao, J., Zhang, M., Wang, Q., Chen, B., Hou, Y., & Lu, K. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s193583 · Cited by 22
Immunotherapy in lung cancer brain metastases
Paisana, E., Cascão, R., Alvoeiro, M., Félix, F., Martins, G., Guerreiro, C., Roque, R., Cruz, R., Pacheco, T. R., Amado, A. C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00901-0 · Cited by 23
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
Steendam, C. M. J., Veerman, G., Pruis, M. A., Atmodimedjo, P. N., Paats, M. S., van der Leest, C., von der Thüsen, J. H., Yick, D. C. Y., Hoop, E. O., Koolen, S. L. W., et al. (2020) · Cancers · doi:10.3390/cancers12113179 · Cited by 21
A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting
Terrenato, I., Ercolani, C., Benedetto, A. D., Gallo, E., Melucci, E., Casini, B., Rollo, F., Palange, A., Visca, P., Pescarmona, E. O., et al. (2022) · Cancers · doi:10.3390/cancers14122971 · Cited by 21
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
Kato, T., Casarini, I., Cobo, M., Finn, C. F., Hegi‐Johnson, F., Lü, S., Özgüroğlu, M., & Ramalingam, S. S. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107414 · Cited by 21
Osimertinib for patients with EGFR T790M mutation-positive non–small-cell lung cancer and a poor performance status
Nakashima, K., Kimura, M., Akamatsu, H., Daga, H., Imai, H., Taira, T., Ko, R., Hisamatsu, Y., Nishino, K., Sugimoto, T., et al. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz041 · Cited by 21
Management of leptomeningeal metastases in non-small cell lung cancer
Patil, S. G., & Rathnum, K. K. (2019) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_74_19 · Cited by 21
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
Nadler, E., Pavilack, M., Espirito, J. L., Clark, J., & Fernandes, A. W. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01221-4 · Cited by 21
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC
Protopapa, M., Kouloulias, V., Nikoloudi, S., PAPADIMITRIOU, C. A., Gogalis, G., & Zygogianni, A. G. (2019) · Journal of Oncology · doi:10.1155/2019/3267409 · Cited by 21
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
Liu, X., Hong, L., Nilsson, M., Hubert, S. M., Wu, S., Rinsurongkawong, W., Lewis, J., Spelman, A., Roth, J., Swisher, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.023 · Cited by 20
Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery
Singh, S. A., McDermott, D. M., & Mattes, M. D. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.09.082 · Cited by 20
Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
Rossi, A., & Galetta, D. (2022) · Cancers · doi:10.3390/cancers14030832 · Cited by 20
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
Lee, E. J., Oh, S. Y., Lee, Y. W., Kim, J. Y., Kim, M.-J., Kim, T. H., Lee, J. B., Hong, M. H., Lim, S. M., Baum, A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2951 · Cited by 21
KIT Mutations Correlate with Higher Galectin Levels and Brain Metastasis in Breast and Non-Small Cell Lung Cancer
Funkhouser, A., Strigenz, A. M., Blair, B. B., Miller, A. P., Shealy, J. C., Ewing, J. A., Martin, J., Funk, C. R., Edenfield, W. J., & Blenda, A. V. (2022) · Cancers · doi:10.3390/cancers14112781 · Cited by 19
First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
Zhou, Q. H., Yu, Y., Xing, L., Cheng, Y., Wang, Y., Pan, Y., Fan, Y., Shi, J., Zhang, G., Cui, J., et al. (2024) · Med · doi:10.1016/j.medj.2024.09.002 · Cited by 24
Self-citation
Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma
Li, R., Zhou, X., Yao, H.-J., & Li, L. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737934 · Cited by 19
EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
Liu, B., Liu, H., Ma, Y., Ding, Q., Zhang, M., Liu, X., & Liu, M. (2021) · Cancer Medicine · doi:10.1002/cam4.4192 · Cited by 20
CACA guidelines for holistic integrative management of lung cancer
Wang, J. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00069-w · Cited by 19
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
Cao, Y., Qiu, X., Xiao, G., Hu, H., & Lin, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221575 · Cited by 18
Leveraging translational insights toward precision medicine approaches for brain metastases
Kim, A. E., Nieblas‐Bedolla, E., de Sauvage, M. A., & Brastianos, P. K. (2023) · Nature Cancer · doi:10.1038/s43018-023-00585-0 · Cited by 19
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches
Levis, M., Gastino, A., Giorgi, G. D., Mantovani, C., Bironzo, P., Mangherini, L., Ricci, A. A., Ricardi, U., Cassoni, P., & Bertero, L. (2023) · Cancers · doi:10.3390/cancers15184622 · Cited by 19
The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
Gu, W., Liu, P., Tang, J., Lai, J., Wang, S., Zhang, J., Xu, J., Deng, J., Yu, F., Shi, C., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288468 · Cited by 18
Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers
Sato, H., Offin, M. D., Kubota, D., Yu, H. A., Wilhelm, C., Toyooka, S., Somwar, R., Kris, M. G., & Ladanyi, M. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.019 · Cited by 18
Review of the diagnosis and treatment of brain metastases
Narita, Y., Sato, S., & Kayama, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab182 · Cited by 18
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review
McAleavey, P. G., Walls, G., & Chalmers, A. J. (2022) · CNS Oncology · doi:10.2217/cns-2021-0015 · Cited by 18
A multidisciplinary management algorithm for brain metastases
Ramos, A. D., Giantini-Larsen, A., Pannullo, S. C., Brandmaier, A., Knisely, J. P. S., Magge, R., Wilcox, J. A., Pavlick, A. C., Ma, B., Pisapia, D. J., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac176 · Cited by 18
Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review
Wang, N., Zhang, Y., Mi, Y., Deng, H., Chen, G., Tang, Z., Mao, J., Cui, S., Zhang, Y., & Wang, L. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-605 · Cited by 18
Application of EGFR-TKIs in brain tumors, a breakthrough in future?
Feng, S., Liu, H., Yun, C., Zhu, W. Z., & Pan, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06448-9 · Cited by 19
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib
Piotrowska, Z., Ahn, M., Voon, P. J., Pang, Y. K., How, S. H., Kim, S., Cortinovis, D. L., de Castro, J., Tiseo, M., Rodríguez‐Abreu, D., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0960 · Cited by 17
Self-citation
A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player
Zhou, Y., Yu, F., Zhao, Y., Zeng, Y., Yang, X., Chu, L., Chu, X., Li, Y., Zou, L., Guo, T., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1145 · Cited by 18
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
Yoh, K., Hirashima, T., Saka, H., Kurata, T., Ohe, Y., Hida, T., Mellemgaard, A., Verheijen, R. B., Ou, X., Ahmed, G. F., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00806-5 · Cited by 17
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, J., Piotrowska, Z., Soo, R. A., Cho, B. C., & Lim, S. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144099 · Cited by 17
Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review
Khasraw, M., Yalamanchili, P., Santhanagopal, A., Wu, C., Salas, M., Meng, J., Karnoub, M., Esker, S., & Felip, E. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02799-9 · Cited by 19
Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings
Attili, I., Corvaja, C., Spitaleri, G., Aliaga, P. T., Signore, E. D., Passaro, A., & de Marinis, F. (2024) · Cancers · doi:10.3390/cancers16142589 · Cited by 17
Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Melosky, B. L. (2018) · Current Oncology · doi:10.3747/co.25.3839 · Cited by 17
Front-line Therapy in Advanced Non–Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis
Li, X., Lin, J.-Z., & Yu, S. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.006 · Cited by 17
Metastasis to the Central Nervous System
Boire, A. A. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000939 · Cited by 17
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
Zhu, J., Yang, Q., & Xu, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091500 · Cited by 17
Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
Chen, L., Zhou, Y., Gan, C., Wang, X., Liu, Y., Dong, C., He, R., & Yang, J. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2069254 · Cited by 17
First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
Tatineni, V., O'Shea, P. J., Ozair, A., Khosla, A. A., Saxena, S., Rauf, Y., Jia, X., Murphy, E. S., Chao, S. T., Suh, J. H., et al. (2023) · Cancers · doi:10.3390/cancers15082382 · Cited by 16
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tétu, P., Lebbé, C., Ciccolini, J., Meyer, N., & Paci, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104384 · Cited by 16
Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance
Lin, X., Jia, Y.-L., Dong, X., Shen, J. F., Jin, Y., Li, Y., Wang, F., Anenberg, E., Zhou, J., Zhu, J., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00982 · Cited by 16
Real-World Disease Burden and Outcomes of Brain Metastases in EGFR Mutation-Positive Non-Small-Cell Lung Cancer
Nadler, E., Espirito, J. L., Pavilack, M., Baidoo, B., & Fernandes, A. W. (2020) · Future Oncology · doi:10.2217/fon-2020-0280 · Cited by 16
Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study
Wang, X., Cai, J., Zeng, Z., & Liu, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08581-2 · Cited by 16

Authors: Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Han, J.-Y., Katakami, N., Kim, H. R., Hodge, R., Kaur, P., Brown, A. P., Ghiorghiu, D., Papadimitrakopoulou, V. A., & Mok, T. S. K.
Affiliations: Yonsei University (KR)
ORCID: Wu, Yi-Long
Ahn, Myung-Ju
Garassino, Marina Chiara
Han, Ji-Youn
Katakami, Nobuyuki
Kim, Hye Ryun
Hodge, Rachel
Papadimitrakopoulou, Vassiliki A.
Mok, Tony S.K.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2018-09-10
Volume: 36
Issue: 26
Pages: 2702-2709
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2018.77.9363
OpenAlex: W2887416920
Cited by: 517
References: 18
Citations by year: 2026: 30 · 2025: 59 · 2024: 63 · 2023: 79 · 2022: 66 · 2021: 75 · 2020: 70 · 2019: 62 · 2018: 13
FWCI: 41.63
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Brain Metastases and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: osimertinib, T790M mutation, advanced non-small cell lung cancer, central nervous system metastasis, EGFR tyrosine kinase inhibitors, CNS penetration, AURA3 trial, subgroup analysis
MeSH terms: Pemetrexed, Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Pyrimidines, Carboplatin, Protein Kinase Inhibitors, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks